East Coast Biotech Roundup: Bristol, PTC, Ophthotech, & More
Xconomy Ophthotech is currently running three big Phase 3 studies testing the drug in combination with other wet AMD therapies like Novartis/Genentech’s bevacizumab (Lucentis). Shares of Ophthotech jumped more than 24 percent after news of the deal broke. |
Source: Wet Macular Degeneration News From Google News
Zennie Abraham | Zennie Abraham or “Zennie62” is the founder of Zennie62Media which consists of zennie62blog.com and a multimedia blog news aggregator and video network, and 78-blog network, with social media and content development services and consulting. Zennie is a pioneer video blogger, YouTube Partner, social media practitioner, game developer, and pundit. Note: news aggregator content does not reflect the personal views of Mr. Abraham.